Download PDF
Krankenhauspsychiatrie 2002; 13(Sh1): 38-43
DOI: 10.1055/s-2002-34602
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Therapie der bipolaren Depression

The Treatment of Bipolar DepressionJ.  Nebe1
  • 1Klinik für Psychiatrie und Psychotherapie der Universität Essen (Rheinische Kliniken Essen)
Further Information

Publication History

Publication Date:
09 October 2002 (online)

    Permissions and Reprints

Zusammenfassung

Bei Depressionen im Rahmen eines bipolaren Verlaufs soll eine Behandlung mit Antidepressiva nur unter gleichzeitiger medikamentöser Stimmungsstabilisierung stattfinden, damit das Risiko des Umschlagens in die Manie und des Rapid cyclings vermindert wird. Die Antidepressiva werden meist in Analogie zur unipolaren Depression eingesetzt; Studien existieren nur wenige. Nach einer schweren Depression soll bei bipolarem Verlauf neben dem Stimmungsstabilisierer eine Erhaltungstherapie mit dem zuletzt verwendeten Antidepressivum folgen (ausgenommen bei Rapid cycling), nach psychotischer Depression auch mit einem Neuroleptikum. Es werden die Möglichkeiten bei Therapieresistenz beschrieben. Unter den Stimmungsstabilisierern wirken nur Lithium und Lamotrigin per se antidepressiv. Von den neueren Antipsychotika erhofft man sich auch in Bezug auf die Depression einen stimmungsstabilisierenden Effekt.

Abstract

In bipolar disorder, the treatment with an antidepressant has to be combined with a mood stabilizer in order to avoid a switch to mania and the development of rapid cycling. As there are only a few studies, antidepressants are used in analogy to unipolar depression. After a severe bipolar depression, a maintenance therapy with the antidepressant last used is necessary parallel to mood stabilization (except in rapid cycling); after psychotic depression also with a neuroleptic. The options in case of therapy resistance are discussed. Among the mood stabilizers, only lithium and lamotrigine possess an antidepressant effect per se. The new antipsychotics might have mood-stabilizing effects against depression also.

Schlüsselwörter

Bipolare affektive Störung - Depression - Therapieresistenz - Switch

Key words

Bipolar disorder - Depression - Therapy resistance - Switch

Literatur

  • 1 Benazzi F. Prevalence and clinical correlates of residual depressive symptoms in bipolar II disorder.  Psychother Psychosom. 2001a;  70 232-238
    Google Scholar
  • 2 Benazzi F. The clinical picture of bipolar II outpatient depression in private practice.  Psychopathology. 2001b ;  34 81-84
    CrossrefGoogle Scholar
  • 3 Perugi G, Micheli C, Akiskal H S, Madaro D, Socci C, Quilici C, Musetti L. Polarity of the first episode, clinical characteristics, and course of manic depressive illness: a systematic retrospective investigation of 320 bipolar I patients.  Compr Psychiatry. 2000;  41 13-18
    CrossrefGoogle Scholar
  • 4 Grunze H, Walden J, Dittmann S, Berger M, Bergmann A, Bräunig P, Dose M, Emrich H M, Gastpar M, Greil W, Krüger S, Möller H J, Uebelhack R. Psychopharmakotherapie bipolarer affektiver Erkrankungen.  Nervenarzt. 2002;  73 4-19
    CrossrefGoogle Scholar
  • 5 Mukherjee S, Rosen A M, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients.  Arch Gen Psychiatry. 1986;  43 342-346
    Google Scholar
  • 6 Kane J M. Tardive dyskinesia in affective disorders.  J Clin Psychiatry. 1999;  60 (Suppl 5) 43-49
    Google Scholar
  • 7 Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.  J Clin Psychopharmacol. 1998;  18 455-460
    CrossrefGoogle Scholar
  • 8 Fieve R R, Platman S R, Plutchik R R. The use of lithium in affective disorders. I. Acute endogenous depression.  Am J Psychiatry. 1968;  125 487-491
    Google Scholar
  • 9 Merideth C H, Feighner J P. The use of bupropion in hospitalized depressed patients.  J Clin Psychiatry. 1983;  44 (5 Pt 2) 85-87
    Google Scholar
  • 10 Fabre L F, Brodie H K, Garver D, Zung W W. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients.  J Clin Psychiatry. 1983;  44 88-94
    Google Scholar
  • 11 Baumhackl U, Biziere K, Fischbach R, Geretsegger C, Hebenstreit G, Radmayr E, Stabl M. Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.  Br J Psychiatry Suppl. 1989;  Oct (6) 78-83
    Google Scholar
  • 12 Cohn J B, Collins G, Ashbrook E, Wernicke J F. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder.  Int Clin Psychopharmacol. 1989;  4 313-322
    CrossrefGoogle Scholar
  • 13 Himmelhoch J M, Thase M E, Mallinger A G, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression.  Am J Psychiatry. 1991;  148 910-916
    CrossrefGoogle Scholar
  • 14 Sachs G S, Lafer B, Stoll A L, Banov M, Thibault A B, Tohen M, Rosenbaum J F. A double-blind trial of bupropion versus desipramine for bipolar depression.  J Clin Psychiatry. 1994;  55 391
    Google Scholar
  • 15 Young L T, Joffe R T, Robb J C, MacQueen G M, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression.  Am J Psychiatry. 2000;  157 124-126
    Google Scholar
  • 16 Nemeroff C B, Evans D L, Gyulai L, Sachs G S, Bowden C L, Gergel I P, Oakes R, Pitts C D. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression.  Am J Psychiatry. 2001;  158 906-912
    CrossrefGoogle Scholar
  • 17 Kupfer D J, Chengappa K N, Gelenberg A J, Hirschfeld R M, Goldberg J F, Sachs G S, Grochocinski V J, Houck P R, Kolar A B. Citalopram as adjunctive therapy in bipolar depression.  J Clin Psychiatry. 2001;  62 985-990
    Google Scholar
  • 18 Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial.  Acta Psychiatr Scand. 2001;  104 104-109
    CrossrefGoogle Scholar
  • 19 Thase M E, Mallinger A G, McKnight D, Himmelhoch J M. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression.  Am J Psychiatry. 1992;  149 195-198
    CrossrefGoogle Scholar
  • 20 Walden J, Grunze H, Schlösser S, Berger M, Bergmann A, Bräunig P, Dose M, Emrich H M, Gastpar M, Greil W, Möller H J, Übelhack R. Empfehlungen für die Behandlung bipolarer affektiver Störungen.  Psychopharmakotherapie. 1999;  6 115-123
    Google Scholar
  • 21 Altshuler L, Kiriakos L, Calcagno J, Goodman R, Gitlin M, Frye M, Mintz J. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review.  J Clin Psychiatry. 2001;  62 612-616
    CrossrefGoogle Scholar
  • 22 Prien R F, Klett C J, Caffey E M. Lithium carbonate and imipramine in prevention of affective episodes.  Arch Gen Psychiatry. 1973;  29 420-425
    Google Scholar
  • 23 Prien R F, Kupfer D J, Mansky P A, Small J G, Tuason V B, Voss C B, Johnson W E. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination.  Arch Gen Psychiatry. 1984;  41 1096-1104
    Google Scholar
  • 24 Quitkin F M, Kane J, Rifkin A, Ramos-Lorenzi J R, Nayak D V. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study.  Arch Gen Psychiatry. 1981;  38 902-907
    Google Scholar
  • 25 Kane J M, Quitkin F M, Rifkin A, Ramos-Lorenzi J R, Nayak D D, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison.  Arch Gen Psychiatry. 1982;  39 1065-1069
    CrossrefGoogle Scholar
  • 26 Johnstone E C, Owens D G, Lambert M T, Crow T J, Frith C D, Done D J. Combination tricyclic antidepressant and lithium maintenance medication in unipolar and bipolar depressed patients.  J Affect Disord. 1990;  20 225-233
    CrossrefGoogle Scholar
  • 27 Calabrese J R, Suppes T, Bowden C L, Sachs G S, Swann A C, McElroy S L, Kusumakar V, Ascher J A, Earl N L, Greene P L, Monaghan E T. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group.  J Clin Psychiatry. 2000;  61 841-850
    Google Scholar
  • 28 Kusumakar V, Yatham L, Kutcher S, O'Donovan C. Use of topiramate in rapid cycling bipolar women. CNPS 2000
    Google Scholar
  • 29 Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C. Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial.  Neuropsychopharmacology. 1999;  20 380-385
    CrossrefGoogle Scholar
  • 30 Colombo C, Lucca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction.  Psychiatry Res. 2000;  95 43-53
    CrossrefGoogle Scholar
  • 31 Benedetti F, Barbini B, Campori E, Fulgosi M C, Pontiggia A, Colombo C. Sleep phase advance and lithium to sustain the antidepressant effect of total sleep deprivation in bipolar depression: new findings supporting the internal coincidence model?.  J Psychiatr Res. 2001a;  35 323-329
    CrossrefGoogle Scholar
  • 32 Benedetti F, Colombo C, Barbini B, Campori E, Smeraldi E. Morning sunlight reduces length of hospitalization in bipolar depression.  J Affect Disord. 2001b;  62 221-223
    CrossrefGoogle Scholar
  • 33 Frye M A, Denicoff K D, Bryan A L, Smith-Jackson E E, Ali S O, Luckenbaugh D, Leverich G S, Post R M. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients.  Am J Psychiatry. 1999;  156 1909-1914
    Google Scholar
  • 34 Bottlender R, Rudolf D, Strauss A, Möller H J. Are low basal serum levels of the thyroid stimulating hormone (b-TSH) a risk factor for switches into states of expansive syndromes (known in Germany as „maniform syndromes”) in bipolar I depression?.  Pharmacopsychiatry. 2000;  33 75-77
    Article in Thieme ConnectGoogle Scholar
  • 35 Cole D P, Thase M E, Mallinger A G, Soares J C, Luther J F, Kupfer D J, Frank E. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function.  Am J Psychiatry. 2002;  159 116-121
    CrossrefGoogle Scholar
  • 36 Ciapparelli A, Dell'Osso L, Tundo A, Pini S, Chiavacci M C, di Sacco I, Cassano G B. Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression.  J Clin Psychiatry. 2001;  62 552-555
    Google Scholar
  • 37 Daly J J, Prudic J, Devanand D P, Nobler M S, Lisanby S H, Peyser S, Roose S P, Sackeim H A. ECT in bipolar and unipolar depression: differences in speed of response.  Bipolar Disord. 2001;  3 95-104
    CrossrefGoogle Scholar
  • 38 El-Mallakh R S. An open study of methylphenidate in bipolar depression.  Bipolar Disord. 2000;  2 56-59
    CrossrefGoogle Scholar
  • 39 Sporn J, Ghaemi S N, Sambur M R, Rankin M A, Recht J, Sachs G S, Rosenbaum J F, Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review.  Ann Clin Psychiatry. 2000;  12 137-140
    CrossrefGoogle Scholar
  • 40 Perugi G, Toni C, Ruffolo G, Frare F, Akiskal H. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.  Pharmacopsychiatry. 2001;  34 137-141
    Article in Thieme ConnectGoogle Scholar
  • 41 Chengappa K N, Levine J, Gershon S, Mallinger A G, Hardan A, Vagnucci A, Pollock B, Luther J, Buttenfield J, Verfaille S, Kupfer D J. Inositol as an add-on treatment for bipolar depression.  Bipolar Disord. 2000;  2 47-55
    CrossrefGoogle Scholar
  • 42 Angst J. Switch from depression to mania - a record study over decades between 1920 and 1982.  Psychopathology. 1985;  18 140-154
    CrossrefGoogle Scholar
  • 43 Wehr T A, Goodwin F K. Rapid cycling in manic-depressives induced by tricyclic antidepressants.  Arch Gen Psychiatry. 1979;  36 555-559
    Google Scholar
  • 44 Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L. Course of the manic-depressive cycle and changes caused by treatment.  Pharmakopsychiatr Neuropsychopharmakol. 1980;  13 156-167
    Google Scholar
  • 45 Calabrese J R, Bowden C L, Sachs G S, Ascher J A, Monaghan E, Rudd G D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.  J Clin Psychiatry. 1999;  60 79-88
    CrossrefGoogle Scholar
  • 46 Bottlender R, Rudolf D, Strauss A, Möller H J. Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression.  Eur Arch Psychiatry Clin Neurosci. 1998;  248 296-300
    CrossrefGoogle Scholar
  • 47 Vieta E, Martínez-Arán A, Colom F, Benabarre A, Reinares M, Gastó C. Treatment of bipolar depression: paroxetine vs. venlafaxine.  Int J Neuropsychopharmacol. 2000;  3 (Suppl 1) S336
    Google Scholar
  • 48 Amsterdam J D, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression.  J Affect Disord. 2000;  59 225-229
    CrossrefGoogle Scholar
  • 49 Thase M E, Sachs G S. Bipolar depression: pharmacotherapy and related therapeutic strategies.  Biol Psychiatry. 2000;  48 558-572
    CrossrefGoogle Scholar
  • 50 Colombo C, Benedetti F, Barbini B, Campori E, Smeraldi E. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression.  Psychiatry Res. 1999;  86 267-270
    CrossrefGoogle Scholar
  • 51 Calabrese J R. Lamotrigine and the treatment of bipolar disorders. Introduction.  Eur Neuropsychopharmacol. 1999;  9 (Suppl 4) S107-S108
    CrossrefGoogle Scholar
  • 52 Worrall E P, Moody J P, Peet M, Dick P, Smith A, Chambers C, Adams M, Naylor G J. Controlled studies of the acute antidepressant effects of lithium.  Br J Psychiatry. 1979;  135 255-262
    Google Scholar
  • 53 Adli M, Bschor T, Canata B, Döpfmer S, Bauer M. Lithium in der Behandlung der akuten Depression.  Fortschr Neurol Psychiatr. 1998;  66 435-441
    Google Scholar
  • 54 Tondo L, Baldessarini R J, Hennen J, Floris G, Silvetti F, Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients.  J Clin Psychiatry. 1998;  59 405-414
    CrossrefGoogle Scholar
  • 55 Ghaemi S N, Goodwin F K. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use.  J Affect Disord. 2001;  65 281-287
    CrossrefGoogle Scholar
  • 56 Ahlfors U G, Baastrup P C, Dencker S J. Flupenthixol decanoate in recurrent manic depressive illness: a comparison with lithium.  Acta Psychiatr Scand. 1981;  64 226-237
    Google Scholar
  • 57 Esparon J, Kolloori J, Naylor G J, McHarg A M, Smith A H, Hopwood S E. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients.  Br J Psychiatry. 1986;  148 723-725
    Google Scholar
  • 58 Sernyak M J, Griffin R A, Johnson R M, Pearsall H R, Wexler B E, Woods S W. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic.  Am J Psychiatry. 1994;  151 133-135
    Google Scholar
  • 59 Frye M A, Ketter T A, Altshuler L L, Denicoff K, Dunn R T, Kimbrell T A, Cora-Locatelli G, Post R M. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics.  J Affect Disord. 1998;  48 91-104
    CrossrefGoogle Scholar
  • 60 Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush A J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.  Am J Psychiatry. 1999;  156 1164-1169
    Google Scholar
  • 61 Shelton R C, Tollefson G D, Tohen M, Stahl S, Gannon K S, Jacobs T G, Buras W R, Bymaster F P, Zhang W, Spencer K A, Feldman P D, Meltzer H Y. A novel augmentation strategy for treating resistant major depression.  Am J Psychiatry. 2001;  158 131-134
    CrossrefGoogle Scholar
  • 62 Sanger T M, Grundy S L, Gibson P J. et al . Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.  J Clin Psychiatry. 2001;  62 273-281
    Google Scholar
  • 63 Tohen M, Chengappa K N, Suppes T, Zarate Jr C A, Calabrese J R, Bowden C L, Sachs G S, Kupfer D J, Baker R W, Risser R C, Keeter E L, Feldman P D, Tollefson G D, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.  Arch Gen Psychiatry. 2002;  59 62-69
    CrossrefGoogle Scholar

Dr. med. J. Nebe

Klinik für Psychiatrie und Psychotherapie der Universität Essen
Rheinische Kliniken Essen

Virchowstr. 174

45147 Essen

Email: johannes.nebe@uni-essen.de